JW Therapeutics IPO: Valuation Insights
The core drug candidate’s competitive advantage in the China CAR-T market, a good cornerstone investor lineup and our valuation analysis suggest...
451 Views
JW Therapeutics (药明巨诺) IPO: Free Options for Potential License-In
We think at the high-end pricing, investors are getting a free option for their potential in-license products for JW Therapeutics.
419 Views
JW Therapeutics IPO Initiation: Potent Medicine
JW’s core drug candidate’s competitive advantage is supported by its potential best-in-class safety profile with competitive efficacy, physicians’...
374 Views
JW Therapeutics (药明巨诺) Pre-IPO: Pricing with In-License Potential
We provide a bottom-up rNPV based valuation for its key drugs, plus additional valuation for the potential in-licensing from Juno
469 Views
ECM Weekly (18 October 2020) - Lufax, Simcere, KWG Living, GDS, Jacobio
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...
378 Views